Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
Brief Summary: This is a phase 2, randomized, double blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with Cisplatin \& Capecitabine in the treatment of subjects with Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.


Options:
A: Arm Label: Phase 2 Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: Cisplatin, Drug: Placebo | Arm Label: Phase 1b; Type: OTHER; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: AMG 102; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2 Arm C
B: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 3mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 10mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386 placebo, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: AMG 386 placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: AMG 386 10mg/kg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: AMG 386 3mg/kg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): B
C: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 (S-1) | Arm Label: 2; Type: OTHER; Interventions: Procedure: Surgery | Intervention Type: DRUG; Name: TS-1 (S-1); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): 2

Answer: B